Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation (Q39091696)

From Wikidata

Jump to navigation Jump to search

scientific article published on 26 September 2013

Language	Label	Description	Also known as
English	Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation	scientific article published on 26 September 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

2

object named as

Choung-Soo Kim

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

author name string

Ji-Young Song

1

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Je-Hwan Lee

3

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Se Jin Jang

4

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Sang-wook Lee

5

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Jung Jin Hwang

6

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Chulsoo Lim

7

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Gilnam Lee

8

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Jeongbeob Seo

9

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Suk Young Cho

10

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Jene Choi

11

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

publication date

26 September 2013

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

31

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

1458-1465

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Personalized medicine in lung cancer: what we need to know.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Gefitinib-resistance is related to BIM expression in non-small cell lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Tumour cell survival signalling by the ERK1/2 pathway

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Analysis of the transcriptional program induced by Raf in epithelial cells

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

High-throughput oncogene mutation profiling in human cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0030-0

21 January 2018

Identifiers

10.1007/S10637-013-0030-0

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

release_v3dm3mevqnhsxnccpsaxevtmoy

1 reference

https://api.fatcat.wiki/v0/release/v3dm3mevqnhsxnccpsaxevtmoy

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39091696&oldid=2202534570"